ZYBT1, a potent, irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer

Bruton's tyrosine kinase (BTK) plays a central and pivotal role in controlling the pathways involved in the pathobiology of cancer, rheumatoid arthritis (RA), and other autoimmune disorders. ZYBT1 is a potent, irreversible, specific BTK inhibitor that inhibits the ibrutinib‐resistant C481S BTK...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Pharmacol Res Perspect
Autors principals: Ghoshdastidar, Krishnarup, Patel, Hoshang, Bhayani, Hitesh, Patel, Ankit, Thakkar, Kinjal, Patel, Dinesh, Sharma, Manoranjan, Singh, Jaideep, Mohapatra, Jogeswar, Chatterjee, Abhijit, Patel, Dipam, Bahekar, Rajesh, Sharma, Rajiv, Gupta, Lakshmikant, Patel, Nirmal, Giri, Poonam, Srinivas, Nuggehally R., Jain, Mukul, Bandyopadhyay, Debdutta, Patel, Pankaj R., Desai, Ranjit C.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7424564/
https://ncbi.nlm.nih.gov/pubmed/32790160
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.565
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars